Experience
AstraZeneca LP
SigmaPharm Laboratories
Representing AstraZeneca in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.
AstraZeneca LP v. SigmaPharm Laboratories, 1:15-cv-01000, D. Del., Judge Andrews
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Novartis Pharmaceuticals Corporation et al.
Duchesnay Inc. v. Actavis Laboratories FL, Inc. et al.
Duchesnay Inc.
Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.
Grünenthal GmbH et al.
BioDelivery Sciences International, Inc. et al. v. Alvogen PB Research & Development LLC et al.
BioDelivery Sciences International, Inc. et al.
Alexander Sr. v. BMW of North America LLC, et al.
BMW of North America LLC, et al.
Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC et al.
Biogen Int’l GmbH
Real Time Social Inventions LLC v. Conduit USA, Inc. et al.
Conduit USA, Inc. et al.
Salient Systems Corporation v. Hawk Technology Systems LLC et al.
Salient Systems Corporation
Koninklijke Philips N.V. et al. v. Amerlux, LLC, et al.
Koninklijke Philips N.V.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.